Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
A health care worker during the phase 3 COVID-19 vaccine trial by Pfizer and BioNTech in Ankara, Turkey, in October. Photo: Dogukan Keskinkilic/Anadolu Agency via Getty Images
The U.K. government announced Wednesday it approved Pfizer-BioNTech's COVID-19 vaccine, which "will be made available across the U.K. from next week."
Why it matters: The U.K. has beaten the U.S. to become the first Western country to give emergency approval for a vaccine that's found to be 95% effective with no serious side effects against a virus that's killed nearly 1.5 million people globally.
- Per Axios' Jonathan Swan, FDA commissioner Stephen Hahn was summoned to the White House Tuesday to explain why he hadn't moved faster to approve the Pfizer-BioNTech vaccine.
What they're saying: Health Secretary Matt Hancock tweeted that the U.K. is "the first country in the world to have a clinically approved vaccine for supply."
- Pfizer chair and CEO Albert Bourla said in a statement, "As we anticipate further authorizations and approvals, we are focused on moving with the same level of urgency to safely supply a high-quality vaccine around the world."
The big picture: The U.K. government has ordered 40 million doses of the vaccine, which is enough to inoculate some 20 million people. The nation has one of the highest COVID-19 death rates in Europe, with over 59,000 people losing their lives to the virus.
- The New York Times notes that the U.K. drug regulator's approval testifies to a strategy that's been "the most aggressive in the West," after breaking away from the EU's health regulations and bolstering an old law to fast-track a review on Pfizer-BioNTech's vaccine.
Of note: The Pfizer-BioNTech vaccine has to be stored at temperatures well below freezing (about -94°F or -70°C).
- But the companies say that once delivered it can be kept for up to five days in a fridge after thawing.
For the record: Russia and China have already cleared coronavirus vaccines, but they're not waiting for the results of large-scale clinical trials — prompting scientists to cast doubts on their safety and efficacy.
🎧 Go deeper: Axios Re:Cap interviews Pfizer CEO Albert Bourla.
Editor's note: This article has been updated with new details throughout.